These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 1658554)

  • 1. Use and selectivity of herbimycin A as inhibitor of protein-tyrosine kinases.
    Uehara Y; Fukazawa H
    Methods Enzymol; 1991; 201():370-9. PubMed ID: 1658554
    [No Abstract]   [Full Text] [Related]  

  • 2. Effects of herbimycin A and various SH-reagents on p60v-src kinase activity in vitro.
    Fukazawa H; Mizuno S; Uehara Y
    Biochem Biophys Res Commun; 1990 Nov; 173(1):276-82. PubMed ID: 2175179
    [TBL] [Abstract][Full Text] [Related]  

  • 3. p60v-src causes tyrosine phosphorylation and inactivation of the N-cadherin-catenin cell adhesion system.
    Hamaguchi M; Matsuyoshi N; Ohnishi Y; Gotoh B; Takeichi M; Nagai Y
    EMBO J; 1993 Jan; 12(1):307-14. PubMed ID: 8381351
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Herbimycin A inhibits the association of p60v-src with the cytoskeletal structure and with phosphatidylinositol 3' kinase.
    Hamaguchi M; Xiao H; Uehara Y; Ohnishi Y; Nagai Y
    Oncogene; 1993 Mar; 8(3):559-64. PubMed ID: 8382356
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction by herbimycin A of contact inhibition in v-src-expressed cells.
    Suzukake-Tsuchiya K; Moriya Y; Hori M; Uehara Y; Takeuchi T
    J Antibiot (Tokyo); 1989 Dec; 42(12):1831-7. PubMed ID: 2559910
    [TBL] [Abstract][Full Text] [Related]  

  • 6. v-Src suppresses SHPS-1 expression via the Ras-MAP kinase pathway to promote the oncogenic growth of cells.
    Machida K; Matsuda S; Yamaki K; Senga T; Thant AA; Kurata H; Miyazaki K; Hayashi K; Okuda T; Kitamura T; Hayakawa T; Hamaguchi M
    Oncogene; 2000 Mar; 19(13):1710-8. PubMed ID: 10763828
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Benzoquinonoid ansamycins possess selective tumoricidal activity unrelated to src kinase inhibition.
    Whitesell L; Shifrin SD; Schwab G; Neckers LM
    Cancer Res; 1992 Apr; 52(7):1721-8. PubMed ID: 1551101
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Benzoquinoid ansamycins (herbimycin A and geldanamycin) interfere with the maturation of growth factor receptor tyrosine kinases.
    Sakagami M; Morrison P; Welch WJ
    Cell Stress Chaperones; 1999 Mar; 4(1):19-28. PubMed ID: 10467105
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanism of reversion of Rous sarcoma virus transformation by herbimycin A: reduction of total phosphotyrosine levels due to reduced kinase activity and increased turnover of p60v-src1.
    Uehara Y; Murakami Y; Sugimoto Y; Mizuno S
    Cancer Res; 1989 Feb; 49(4):780-5. PubMed ID: 2463877
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction of hsp 72/73 by herbimycin A, an inhibitor of transformation by tyrosine kinase oncogenes.
    Murakami Y; Uehara Y; Yamamoto C; Fukazawa H; Mizuno S
    Exp Cell Res; 1991 Aug; 195(2):338-44. PubMed ID: 2070817
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Specific inhibition of cytoplasmic protein tyrosine kinases by herbimycin A in vitro.
    Fukazawa H; Li PM; Yamamoto C; Murakami Y; Mizuno S; Uehara Y
    Biochem Pharmacol; 1991 Oct; 42(9):1661-71. PubMed ID: 1656993
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of herbimycin A and its derivatives on growth and differentiation of Ph1-positive acute lymphoid leukemia cell lines.
    Sato S; Honma Y; Hozumi M; Hayashi Y; Matsuo Y; Shibata K; Omura S; Hino K; Tomoyasu S; Tsuruoka N
    Leuk Res; 1994 Mar; 18(3):221-8. PubMed ID: 8139288
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Labeling of v-Src and BCR-ABL tyrosine kinases with [14C]herbimycin A and its use in the elucidation of the kinase inactivation mechanism.
    Fukazawa H; Uehara Y; Murakami Y; Mizuno S; Hamada M; Takeuchi T
    FEBS Lett; 1994 Mar; 340(3):155-8. PubMed ID: 8131836
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Involvement of Hsp90 in the quality control of signal transducing proteins].
    Miyata Y
    Tanpakushitsu Kakusan Koso; 2004 May; 49(7 Suppl):862-6. PubMed ID: 15168480
    [No Abstract]   [Full Text] [Related]  

  • 15. [Drugs inhibiting the function of oncogene products, especially protein tyrosine kinases].
    Akiyama T; Ogawara H
    Seikagaku; 1987 Sep; 59(9):1016-20. PubMed ID: 3437165
    [No Abstract]   [Full Text] [Related]  

  • 16. Screening of agents which convert 'transformed morphology' of Rous sarcoma virus-infected rat kidney cells to 'normal morphology': identification of an active agent as herbimycin and its inhibition of intracellular src kinase.
    Uehara Y; Hori M; Takeuchi T; Umezawa H
    Jpn J Cancer Res; 1985 Aug; 76(8):672-5. PubMed ID: 3930444
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A host-dependent temperature-sensitive mutant of Rous sarcoma virus: evidence for host factors affecting transformation.
    Young JC; Liebl E; Martin GS
    Virology; 1988 Oct; 166(2):561-72. PubMed ID: 2845662
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 1H-nmr analysis of herbimycins and dihydro-herbimycins.
    Lin LZ; Blaskó G; Cordell GA
    J Nat Prod; 1988; 51(6):1161-5. PubMed ID: 3236008
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Direct tumorigenic conversion of human gallbladder carcinoma cells by v-src but not by activated c-H-ras oncogene.
    Tatsumoto T; Nakano S; Shimizu K; Ono M; Esaki T; Ohshima K; Niho Y
    Int J Cancer; 1995 Apr; 61(2):206-13. PubMed ID: 7705949
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Microbial secondary metabolites inhibiting oncogene actions].
    Uehara Y
    Seikagaku; 1990 Nov; 62(11):1374-9. PubMed ID: 2077074
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.